直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Prosecution First Blog

Myriad, Mayo, Chakrabarty, Oh My: Strategies for Life Sciences Diagnostics - Part III

April 04, 2017

Authored and Edited by Adriana L. Burgy; Leslie A. McDonell

In Part III of “Myriad, Mayo, Chakrabarty, Oh My:  Strategies for Life Sciences Diagnostics” (links to Part I can be found here and Part II here), we consider the use of examiner interviews and how they can assist into obtaining allowable diagnostic claims. An examiner interview is not a new tool for the prosecutor; it gives an applicant an opportunity to discuss the prior art, the invention, and potential claim amendments in one instance with an examiner. While the gold standard is an in-person interview, telephone interviews are the norm due to today’s prosecution budgets and the USPTO hoteling options for examiners.

Regardless of the type of interview conducted, it’s an opportunity to gain an examiner’s undivided attention and directly discuss the stumbling blocks facing the application. While an Office Action sets forth the basics of the rejection from an examiner, it may not necessarily provide the entire picture an applicant needs to fully address the examiner’s concerns. Further, applicant and examiner may read aspects of the rejection differently or with different emphasis. Now, add to the mix the current flux of what constitutes patentable subject matter; the scale tips in favor of conducting an examiner interview when faced with a 101 rejection.

The USPTO’s website contains examination guidelines, examples, and other materials directed to subject matter eligibility. (Prosecution Pointer:  The USPTO’s webpage includes a summary chart of recent 101 court decisions that is updated regularly.) But, just as an applicant and examiner can read Office Actions differently, examiners often view and apply the guidance materials differently. Interviews enable an applicant to gain understanding on how a particular examiner is applying the guidelines and what it will take to overcome the subject matter eligibility rejection. Is the 101 rejection a brick wall, a mountain, or a mole hill?

Each art group unit has a “101 specialist.” Depending on the situation, it may be beneficial to request to have a “101 specialist” present during the interview. Given the specialist’s experience in the 101 arena, he/she may be able to shed more light on what is triggering the rejection, the Office’s rationale, potential claim amendments, and other options. Claim amendments are another tool for overcoming 101 and can be a discussion point during the interview. Look beyond the dependent claims for claim amendments; review and mine the specification for additional options for amendments. Another consideration is whether to model claims after those in the USPTO examples. In Part IV, we will examine the USPTO’s life sciences examples and the claims.

Tags

diagnostics, Automated Interview Request, subject matter eligibility

Related Practices

Patent Drafting and Prosecution

Contacts

Adriana L. Burgy
Partner
Washington, DC
+1 202 408 4345
Email

Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Conference

BIA Start-up Festival

May 21, 2026

London

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Conference

2026 Advanced Chemical & Biotech Patent Institute

May 11-12, 2026

San Francisco

Workshop

Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law

May 7, 2026

Cambridge

Panel Discussion

Global Patent Strategies & Litigation: An Exclusive Off-the-Record Conversation with Experienced In-House Leaders

May 5, 2026

London

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP